Purposes: To develop a step-by-step production method for human autologous serum (AS) eye drops that was broadly compliant with US Food and Drug Administration requirements for reinjection of processed biological substances. To determine optimum storage conditions for AS eye drops by measuring the concentration of growth factor peptides (GFP) as a function of storage temperature and storage duration.
D
ilute human serum has been shown to stimulate proliferation of corneal epithelial cells in culture.
1,2 Clinically, diluted serum eye drops derived from the patient's own blood [autologous serum (AS)] promote healing in eyes with neurotrophic keratopathy. 3, 4 This effect is ascribed to the rich concentration of numerous growth factor peptides 5, 6 (GFP) in serum. According to current literature, transforming growth factor b 1 (TGFb 1 ), nerve growth factor (NGF), substance P (SubP), calcitonin gene-related peptide (CGRP), insulinlike growth factor-1 (IGF 1 ), and epidermal growth factor (EGF) are among the most relevant proteins in anesthetic ocular surface disease treatment.
Although several comprehensive laboratory protocols for harvesting AS have been published, [7] [8] [9] the effect of storage conditions on GFP concentration has not been specifically investigated. We developed a sterile protocol for AS eye drop production that is broadly in compliance with US Food and Drug Administration (FDA) requirements for processing biological substances for reinjection and measured the concentration of 6 major GFPs as a function of storage time and temperature.
MATERIALS AND METHODS
This human subject research protocol was approved by the Investigational Review Board of Texas Tech University Health Sciences Center. Three healthy male subjects with an average age of 28 years participated.
Harvesting and Storage of AS
Blood collection was performed using blood-banking standards. Serum processing was performed under sterile, low-pyrogen conditions in the Texas Tech Blood Substitute Production Facility (Lubbock, TX). Specific products used and product suppliers are given in Table 1 .
A 19-gauge winged infusion set connected to a doublemale Luer lock and then attached to an 18-gauge needle was used for the blood draw. A second 18-gauge needle was fitted with a 0.2-mm filter and was introduced into a 150-mL evacuated container to break the vacuum and prevent hemolysis. Under standard sterile conditions with povidone-iodine or chlorhexidine skin prep, 100 mL of whole blood was drawn from the patient into the 150-mL container. Both needles were removed, and a sterile glove was placed over the top of the container for transport. The blood was allowed to clot for 90 minutes at room temperature (+25°C) and then centrifuged in a swinging bucket rotor at 3000g for 15 minutes; this force and duration were chosen based on prior studies. 7 An 18-gauge needle of sufficient length to reach the serum (we used a spinal needle) was attached to an intravenous (IV) infusion line tubing extender, which was attached to a 1.2-mm filter fitted with an 18-gauge needle. Under vacuum, serum was drawn from the collection bottle into a 150-mL evacuated container. Serum was transferred a second time through a 0.45-mm filter into a 500-mL evacuated container. For each transfer, the bottle access stopper was wiped with 100% ethanol before needle insertion. Serum volume was assessed using a balance, assuming 1 mL of serum is equivalent to 1 gm of weight. The empty bottle was weighed before collection for baseline weight. Serum was diluted to 20% concentration by adding 4 parts BSS (balanced salt solution) Plus to the 500-mL bottle using IV tubing. The dilute serum was filtered a final time through a 0.2-mm filter into a 500-mL evacuated container. The serum was then dripped through IVextension tubing with stopcock into individual 2-mL daily-use storage bottles, which had undergone ethylene gas sterilization, placing 1 gm in each bottle. Bottles were stored in a sterile sealed plastic bag at 280°C until analysis.
Storage Conditions
Samples stored at 215°C were thawed and assayed at baseline and 1, 2, 3, and 6 weeks; samples stored at +4°C and +25°C were assayed at baseline and 3, 6, 12, and 24 hours. Samples stored at +37°C (normal body temperature) and +42°C (febrile body temperature) were assayed at baseline; 30 minutes; and 1, 3, and 9 hours. Baseline levels were measured once samples were completely thawed at room temperature, which required approximately 15 minutes at +25°C.
Measurement of Serum Peptide Concentrations
The proteins and other substances assayed, including the method of measurement, are summarized in Table 2 . 1 , and EGF were purchased from R&D Systems (Minneapolis, MN); for human SubP and CGRP were purchased from Cayman Chemical (Ann Arbor, MI); and for human NGF was purchased from Promega (Madison, WI). Serum samples tested for NGF were acidified by incubation with 1 M hydrochloric acid before the ELISA. Serum samples tested for SubP and CGRP were first purified by C-18 column chromatography as suggested by the manufacturer.
Serum endotoxin levels were measured using the Limulus Amebocyte Lysate QCL-1000 assay from Cambrex Inc. (Walkersville, MD).
The rate of lipid peroxidation was used as a proxy for the rate of protein degradation. This was assessed by measuring the concentration of thiobarbituric reactive substances (TBARS) via a method developed and described 10 by one of us (J.S.).
Three in-process control analyses were performed to assess (1) the effect of filtration on serum peptide profile, using isoelectric focusing on PhastGel IEF 3-9 with silver staining done with Pharmacia PhastSystem high-speed electrophoresis (GE Healthcare Bio-Science AB, Uppsala, Sweden) and digital densitometry (Scan Analysis, Biosoft, Cambridge, UK); (2) the effect of filtration on peptide concentration using the concentration of the heaviest tested molecule, TGFb 1 ; and (3) the effect of production on lipid peroxidation, measured by TBARS concentration. The effect of clotting time was investigated by assaying the concentrations of free hemoglobin and TGFb 1 after clotting times of 1, 2, 4, and 6 hours at room temperature (+25°C) to determine the optimal GFP yield with minimal hemolysis. Free hemoglobin was determined using the benzidine method. 11 All experiments and chemical analyses were run in duplicate. Data were expressed as mean 6 SD. Statistical analysis was performing using the Student 2-tailed t test; P , 0.05 was considered significant.
RESULTS
Summary results are given in Table 3 . SubP showed significant degradation at $4°C, TGFb 1 at 37°C and 42°C, NGF at $25°C, and CGRP at all temperatures except 4°C. At 4°C the CGRP concentration showed substantial decline, although not to the level of statistical significance (P , 0.091). The TBARS concentration did not significantly increase at any temperature or time; endotoxin levels had a single significant increase after 3 hours at 37°C (P , 0.029), however the 9-hour value was not significantly different from baseline; this discrepancy is likely due to the small number of test subjects and the large SDs and requires a larger study to assess fully.
The concentration of TGFb 1 was not affected by clotting time (Fig. 1 ). Filtration had a minimal effect on the qualitative peptide profile as demonstrated by isoelectric focusing and densitometry (Fig. 2) . No decrease in TGFb 1 concentration (Fig. 3 ) and no increase in TBARS (Fig. 4) or endotoxin ( Fig. 5 ) concentrations were observed during in-process controls.
DISCUSSION
The relative clinical importance of the major GFP in AS topical ophthalmic therapy is unknown, 5, 6 and it is likely that synergies between peptides exist. The threshold concentrations on the ocular surface and the duration of contact needed for clinical effect are also undefined. Because AS is a biological substance unique to each patient, it is impossible to know individual peptide concentrations with certainty unless a comprehensive ELISA-based analysis is performed, a process which is inaccessible and cost-prohibitive under clinical circumstances. However, storage conditions are controllable, and they can be designed to minimize protein denaturation from baseline (fresh serum) levels. Because heat accelerates peptide hydrolysis, most investigators use frozen storage of packaged AS with refrigerated storage of 1 active bottle. Some authors 12, 13 ascribe therapeutic benefit to AS which has been kept refrigerated for several days or weeks. Although the small number of test subjects limits the strength of statistical analysis, our results do not support this manner of storage. SubP, NGF, and CGRP all showed significant declines in concentration when held at 25°C for 24 hours, with the mean concentration of SubP falling by .50% (P , 0.0001). SubP was 1 of the first GFP with proven clinical benefit in the treatment of neurotrophic keratopathy.
14 Having developed the processing method, a study with a larger number of subjects, and testing of additional serum substances such as vitamin A, could be conducted. It is important to remember that an individual patient will not behave like an ''average'' and that storage conditions should be conservatively selected to TGFb 1  ---9h  3h  NGF  --24 
Cells with dashes indicate decline in concentration not statistically significant at P , 0.05 (Student 2-tailed t test); 215°C tested at baseline and 1, 2, 3, and 6 weeks; +4°C tested at baseline and 3, 6, 12, and 24 hours; +25°C tested at baseline and 1, 3, 6, and 24 hours; +37°C tested at baseline, 30 minutes and 1, 3, and 9 hours; +42°C tested at baseline, 30 minutes, and 1, 3, and 9 hours; LPS, lipopolysaccharide. FIGURE 1. Free hemoglobin and TFGb 1 levels in serum as a function of clotting time before centrifugation. There was no significant change in either protein.
FIGURE 2.
In-process control: effect of filtration on the serum peptide profile. Isoelectric focusing and densitometry showed no qualitative change in the peptide profile as serum traveled through the filtration process. pI = isoelectric point of the protein; when the pH in the gel equals the protein's pI, it no longer migrates within the gel.
encompass the outlier patients showing more rapid degradation.
We believe that for greatest stability, dilute AS should be stored in multiple single-day bottles, which are kept frozen until the day of use at approximately 215°C (a typical home freezer is 220°C to 215°C, 24°F to +5°F). Between administrations the thawed bottle should be refrigerated at no greater than +4°C (a typical home refrigerator is +1.7°C to +4°C, +30°F to +35°F). Patients should be specifically instructed not to place a bottle in their pocket or on a table in a warm location for more than a few moments and to discard bottles that have been left unrefrigerated for more than 2-3 hours. Even under frozen storage conditions, CGRP may show a statistically significant decline in concentration; the clinical importance of this change is unknown.
Human research on the use of topical ophthalmic AS is regulated by the Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the FDA. This office requires that every step in production utilize only materials that are approved for reinjection of substances into the human body (B. Golding, MD, official correspondence, May 2004). Standard laboratory blood-draw tubes used for serum separation are not approved, for example. One major obstacle was finding an approved container for blood collection that could be centrifuged. The only evacuated container of adequate volume approved for reinjection at the time of study design was a total parenteral nutrition bottle. The manufacturer stated that 3000g would not harm the bottle (J. C. Bradley, personal communication with Hospira Inc.), which we confirmed by a trial centrifugation.
The filters utilized in this protocol were selected based on their reported optimal membrane for body fluid filtration (JCB, personal correspondence with Pall Corporation); the manufacturer's Web site specifically describes their use for filtration of ophthalmic drops. The 1.2-, 0.45-, and 0.2-mm filters acted to remove blood clot debris, residual corpuscular elements, and bacteria, respectively. These filters showed no major qualitative effect on the serum peptide profile (Fig. 2) and did not significantly reduce the concentration of the heaviest peptide (Fig. 3) . The filtration process did not cause lipid peroxidation (Fig. 4) .
The FDA limit for endotoxin contamination of sterile water for injection or irrigation is #0.25 endotoxin units/mL (EU/mL) (http://www.fda.gov/ora/inspect_ref/itg/itg40.html). With the exception of the spinal needle, all fluids and disposable medical supplies (other needles, tubing, connectors, evacuated containers, and storage bottles) used were United States Pharmacopeia grade and approved for reinjection. We specifically investigated the effect of filtration on endotoxin levels; because all 3 filters were manufactured, packaged, and sterilized identically with the exception of pore size, we verified the manufacturer's claim that each filter contains ,0.25 EU/mL of lipopolysaccharide (endotoxin) by measuring lipopolysaccharide before and after passage through the final 0.2-mm filter (Fig. 5) . Mean endotoxin level increased by a nonsignificant 0.02 EU/mL and was ,0.2 EU/mL for the final diluted AS product. The use of non-United States Pharmacopeia medical supplies or other filters with different membranes might reduce the final product concentration of GFP and/or increase the endotoxin level to a clinically important degree, and we do not recommend substitution without in-process control testing.
We used a spinal needle (for lumbar puncture) to withdraw serum from the centrifuged total parenteral nutrition (TPN) container. This needle was inexpensive and readily available to our laboratory as it was stocked for hospital use; however, it is not approved for reinjection. An 18-gauge needle 3 or 4 inches in length that is approved for reinjection can be specially ordered; the only difference is the design of the needle tip and hub. The same company often supplies both needles.
We produced AS in the Texas Tech Blood Substitute Production Facility (Lubbock, TX), which is Good FIGURE 5. In-process control: effect of filtration on endotoxin lipopolysaccharide (LPS) concentration in dilute serum. There was no significant increase in endotoxin concentration after passage through the 0.2-mm filter. The FDA upper limit for endotoxin contamination of sterile water for irrigation or injection is 0.25 EU/mL. After dilution = AS diluted to 20% concentration with BSS (balanced salt solution) Plus; after filtration = dilute serum passed through filter with 0.2-mm pore sizes. Manufacturing Practice certified to manufacture sterile, lowpyrogen, protein-based IV biopharmaceuticals for experimental use (note, however, that we did not perform formal sterility testing, which would be required by the FDA for approval for clinical research). A standard blood-banking facility could use our process, with the purchase of a few disposable medical supplies and filters (Table 1) . Because all steps in manufacture before final decanting occur in a closed system, if aseptic technique is used for blood draw, the risk of contamination is minimal unless there is an environmental breach. Ideally, the blood bank would have a laminar flow hood for sterility during decanting into the daily-use dropper bottles. Because the cascade filtration is driven by the intrinsic vacuum of the containers, no specialized equipment is needed.
